Key result
Nanoparticles and adeno-associated viruses enable targeted, minimally invasive therapeutic delivery following myocardial infarction.
Answers are grounded in this paper and cite their sources.
Nanoscale therapeutics have promise for the administration of therapeutic small molecules and biologics to the heart following myocardial infarction. Directed delivery to the infarcted region of the heart using minimally invasive routes is critical to this promise. In this review, we will discuss the advances and design considerations for two nanoscale therapeutics engineered to target the infarcted heart, nanoparticles and adeno-associated viruses.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2020) conducted a review in Myocardial infarction. Targeted nanoscale therapeutics (nanoparticles and adeno-associated viruses) was evaluated. Nanoparticles and adeno-associated viruses are two nanoscale therapeutics engineered for minimally invasive, directed delivery to the infarcted heart following myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: